canyon landscape

Troriluzole in Adult Subjects with Spinocerebellar Ataxia

Home / Patient Care / Take Action / Find a Clinical Trial / Clinical Trials / Troriluzole in Adult Subjects with Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Age Range
  • 18-75
Total Participants
230
Keywords
Primary Sponsor
Biohaven Pharmaceuticals, Inc.